Oxthera develops a novel treatment for patients with the ultra-orphan kidney disease primary hyperoxaluria. In patients, mostly children, this life-threatening disease accumulates oxalate in the body and the oxalate forms insoluble crystals and stones in different organs (kidney, liver, heart and eyes).

ePHex - An OxThera Clinical Trial in Primary Hyperoxaluria, MedicalBeautyHouse, Capio Vårdcentral Ringen, AWT Kliniken, Apoteksgruppen, Apoteket Hägern,

High levels of oxalate cause kidney damage, including crystallization of oxalate in tissues and in the kidney. OxThera AB is a Swedish biotech company developing a new treatment for primary hyperoxaluria (PH) - a rare genetic and devastating disease with fatal outcomes. Currently pharmaceutical treatment is Oxthera develops a novel treatment for patients with the ultra-orphan kidney disease primary hyperoxaluria. In patients, mostly children, this life-threatening disease accumulates oxalate in the body and the oxalate forms insoluble crystals and stones in different organs (kidney, liver, heart and eyes). There is no treatment for primary hyperoxaluria and the patients enter end-stage-renal dialysis within a few years. Primary hyperoxaluria is a rare autosomal recessive inherited disorder of glyoxylate metabolism that causes an endogenous overproduction of oxalate.

Our mission is to bring novel treatment options to rare kidney disease and to partner closely with the medical and patient communities we serve. Ultimately, our goal is to improve quality of life and to extend life expectancy of patients with primary hyperoxaluria. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a severe and often fatal disease in children, and where there are currently no available therapies. The… Read More Matthew Gantz Appointed CEO of Oxthera 2017-07-05 Primary hyperoxaluria is a rare autosomal recessive inherited disorder of glyoxylate metabolism that causes an endogenous overproduction of oxalate. Oxalate cannot be degraded in humans and is mostly eliminated by the kidneys. The oxalate overproduction leads to kidney stones, nephrocalcinosis and kidney damage.

OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria.

01:19 Behandlingsalternativ vid primär hyperoxaluri02:42 Fördelarna med forskning i sällsynta sjukdomar03:50 Kommande milstolpar för

If left untreated, the disease can cause kidney failure and premature death. Primary hyperoxaluria is a rare genetic disorder that affects primarily children causing progressive kidney damage, calcification of the kidneys, and finally kidney failure.

OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients.

/PRNewswire/ -- OxThera AB has been granted three Japanese patents during 2012 and 2013.

Phase III. Invest. ePHex - An OxThera Clinical Trial in Primary Hyperoxaluria, MedicalBeautyHouse, Capio Vårdcentral Ringen, AWT Kliniken, Apoteksgruppen, Apoteket Hägern, Coordinate: 59.3516585061, 17.9669809341. Phone: +46739560288 (www.VREX.se). 46667.
Robotprogrammerare job

In that time, they may be periodically evaluated using urine, stool, and plasma samples as well as echocardiograms and ultrasounds. 2021-02-19 Primary hyperoxaluria is a rare autosomal recessive inherited disorder of glyoxylate metabolism that causes an endogenous overproduction of oxalate. Oxalate cannot be degraded in humans and is mostly eliminated by the kidneys. The oxalate overproduction leads to … OxThera AB is a Swedish biopharmaceutical company developing a new treatment for primary hyperoxaluria (PH) - a rare genetic and devastating disease with fatal outcomes. Currently pharmaceutical treatment is not available and median age of death is 30, if not treated.

Stockholm.
Neurokirurgen mottagning lund

kolla bilar reg nr
gavobrev fastighet skatteverket
bästa barnmorskemottagning solna
subatomär fysik chalmers
natverksdrift

STOCKHOLM, SWEDEN – June 20, 2019. OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label extension part.

We would like to inform you about a study evaluating ePHex - An OxThera Clinical Trial in Primary Hyperoxaluria March 26, 2019 · Qualified patients willing to participate will undergo a 52 week study. In that time, they may be periodically evaluated using urine, stool, and plasma samples as well as echocardiograms and ultrasounds.

STOCKHOLM, Sweden--(BUSINESS WIRE)--OxThera today announced that all 42 patients have been enrolled in their pivotal phase II/III study using Oxabact ™ for the treatment of Primary Hyperoxaluria.

OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for dietary hyperoxaluria and prevention of kidney stones OxThera AB, a Stockholm-based privately-held biopharmaceutical companyand leader in the field of microbiome derived biotherapeutics, today announced a poster presentation showing encouraging Oxabact ® efficacy and safety data from the long-term study OC5-OL-01, at the Annual Meeting of the American Society of Nephrology Kidney Week 2018 in San Diego. 2020-04-06 · STOCKHOLM, April 6, 2020 /PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced today that it 2020-04-06 · OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact® in Patients With Primary Hyperoxaluria Published: Apr 06, 2020 STOCKHOLM , April 6, 2020 /PRNewswire/ -- OxThera AB , a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced today that it has completed enrollment in its Oxabact ePHex phase OxThera AB is a Swedish biotech company developing a new treatment for primary hyperoxaluria - a rare genetic and devastating disease with fatal outcomes. Currently pharmaceutical treatment is not 2019-06-21 · website builders .

In patients, mostly children, this life-threatening disease accumulates oxalate in the body and the oxalate forms insoluble crystals and stones in different organs (kidney, liver, heart and eyes). OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in in Primary Hyperoxaluria. This announcement bolsters the Company’s position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease. Mission: Stockholm-based Oxthera is currently advancing two late-stage clinical products for the treatment of primary and secondary hyperoxaluria, a kidney disease that is caused by the build-up of oxalate in plasma and urine.Primary hyperoxaluria is a rare genetic disorder that affects primarily children causing progressive kidney damage, calcification of the kidneys, and finally kidney failure.